ArticleProteome science2009
Biomarkers of HIV-1 associated dementia: proteomic investigation of sera.
Article in Proteome science, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 52 citations in OpenAlex.
- Omics for searching plasma biomarkers associated with unfavorable COVID-19 progression in hypertensive patients.Scientific reports · 2025Article
- Analysis of Sigma-1 Receptor Antagonist BD1047 Effect on Upregulating Proteins in HIV-1-Infected Macrophages Exposed to Cocaine Using Quantitative Proteomics.Biomedicines · 2024Article
- Article
- Using plasma proteomics to investigate viral infections of the central nervous system including patients with HIV-associated neurocognitive disorders.Journal of neurovirology · 2022Article
- MASS SPECTROMETRY IN VIROLOGICAL SCIENCES.Mass spectrometry reviews · 2020Review
- Plasma Gelsolin: Indicator of Inflammation and Its Potential as a Diagnostic Tool and Therapeutic Target.International journal of molecular sciences · 2018Review
- Microwave & magnetic proteomics of macrophages from patients with HIV-associated cognitive impairment.PloS one · 2017Article
- Proteomics, biomarkers, and HIV-1: A current perspective.Proteomics. Clinical applications · 2016Review
- Macrophage secretome from women with HIV-associated neurocognitive disorders.Proteomics. Clinical applications · 2016Article
- Proteomic analysis of serum from patients with major depressive disorder to compare their depressive and remission statuses.Psychiatry investigation · 2015Article
- Proteomic profiling of SupT1 cells reveal modulation of host proteins by HIV-1 Nef variants.PloS one · 2015Article
- Glycoproteomic analysis identifies human glycoproteins secreted from HIV latently infected T cells and reveals their presence in HIV+ plasma.Clinical proteomics · 2014Article
- Proteomic analysis of saliva in HIV-positive heroin addicts reveals proteins correlated with cognition.PloS one · 2014Article
- Plasma gelsolin protects HIV-1 gp120-induced neuronal injury via voltage-gated K+ channel Kv2.1.Molecular and cellular neurosciences · 2013Article
- Quantitative analysis of differentially expressed saliva proteins in human immunodeficiency virus type 1 (HIV-1) infected individuals.Analytica chimica acta · 2013Article
- Proteomic analysis of early HIV-1 nucleoprotein complexes.Journal of proteome research · 2013Article
- Cathepsin B and cystatin B in HIV-seropositive women are associated with infection and HIV-1-associated neurocognitive disorders.AIDS (London, England) · 2013Article
- Applying proteomic technology to clinical virology.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2013Review
- HIV-1 Vpr modulates macrophage metabolic pathways: a SILAC-based quantitative analysis.PloS one · 2013Article
- Comparison of 4-plex to 8-plex iTRAQ quantitative measurements of proteins in human plasma samples.Journal of proteome research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundNew, more sensitive and specific biomarkers are needed to support other means of clinical diagnosis of neurodegenerative disorders. Proteomics technology is widely used in discovering new biomarkers. There are several difficulties with in-depth analysis of human plasma/serum, including that there is no one proteomic platform that can offer complete identification of differences in proteomic profiles. Another set of problems is associated with heterogeneity of human samples in addition intrinsic variability associated with every step of proteomic investigation. Validation is the very last step of proteomic investigation and it is very often difficult to validate potential biomarker with desired sensitivity and specificity. Even though it may be possible to validate a differentially expressed protein, it may not necessarily prove to be a valid diagnostic biomarker.
resultsIn the current study we report results of proteomic analysis of sera from HIV-infected individuals with or without cognitive impairment. Application of SELDI-TOF analysis followed by weak cation exchange chromatography and 1-dimensional electrophoresis led to discovery of gelsolin and prealbumin as differentially expressed proteins which were not detected in this cohort of samples when previously investigated by 2-dimensional electrophoresis with Difference Gel Electrophoresis technology.
conclusionValidation using western-blot analysis led us to conclude that relative change of the levels of these proteins in one patient during a timeframe might be more informative, sensitive and specific than application of average level estimated based on an even larger cohort of patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.